Genetika+ obtains CE mark for NeuroKaire to optimise MDD treatment
Genetika+ has received the CE-IVD mark for NeuroKaire, a simple blood test that aids physicians in prescribing optimal treatment for major depressive disorder (MDD). The Israeli company developed